The House of Lords Science and Technology Committee opened an inquiry into how artificial intelligence can accelerate personalized medicine and clinical trials, probing barriers between early research, trial readiness and NHS‑wide implementation. The review comes alongside government aims to use AI to deliver trial‑ready drugs within 100 days by 2030. In parallel, Swiss startup Rivia raised $15 million to scale an "agentic" AI platform that unifies trial data in real time and automates data‑quality workflows for sponsors. Together, the moves signal a government‑industry push to operationalize AI in trial design, site selection, and data curation while regulators and committees evaluate governance and clinical safety questions.